
North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Health Information Designs, Inc.

October 2011

Welcome to the October 2011 edition of the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, Inc. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, Inc. (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidndmedicaid.com, or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

The October 2011 newsletter provides information regarding significant new dosage forms introduced in 2011. Also included is a prior authorization update and the top 25 drug list of second quarter 2011 by cost and claims count.

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, Inc. at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at info@hidinc.com.



Helpful Numbers

PA Help Desk 866-773-0695
To fax PAs 866-254-0761
To report adverse reactions 800-FDA-1088

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Significant New Dosage Forms-2011	2
Prior Authorization Update	2
Top 25 by Cost and Claims Count	3
Health Information Designs, Inc.	4

Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, www.hidndmedicaid.com.

Significant New Dosage Forms - 2011

Brand/Generic	Description
Abstral (fentanyl)	Sublingual tablets for management of breakthrough pain in cancer patients tolerant to opioid therapy.
AndroGel (testosterone)	New concentrated formulation (1.62%) topical gel for hypogonadism.
Banzel (rufinamide)	New oral suspension formulation for seizures.
Combivent Respimat (ipratropium/albuterol)	An inhalation spray for COPD that does not contain chlorofluorocarbons (CFCs).
Complera (emtricitabine/rilpivirine/tenofovir)	New combination formulation for HIV-1 infection in treatment-naïve adults.
Duexis (ibuprofen/famotidine)	New combination NSAID/H2-blocker for patients with rheumatoid arthritis and osteoarthritis.
Gralise (gabapentin)	Once-daily formulation for postherpetic neuralgia.
Juvisync (sitagliptin/simvastatin)	A combination DPP-4 inhibitor and statin for patients with type 2 diabetes and dyslipidemia.
Lazanda (fentanyl)	New nasal spray formulation for breakthrough cancer pain.
Lotemax (loteprednol)	New ophthalmic ointment formulation for post-op inflammation pain.
Makena (hydroxyprogesterone)	Injectable progestin to reduce the risk of preterm birth.
Nithiodote (sodium nitrite/sodium thiosulfate)	Injectable agents for treatment of life-threatening acute cyanide poisoning.
Nucynta ER (tapentadol)	New extended-release formulation for moderate to severe chronic pain.
Oxecta (oxycodone)	Immediate-release tablet formulated to deter abuse.
Phoslyra (calcium acetate)	New oral solution phosphate binder.
Rectiv (nitroglycerin)	New ointment (0.4%) formulation for pain associated with chronic anal fissures.
Rezira (hydrocodone/pseudoephedrine)	New combination antitussive/decongestant oral solution for relief of cold symptoms.
Suprenza (phentermine)	New orally disintegrating tablet for weight loss.
Viramune XR (nevirapine)	New extended-release tablet for HIV-1 infection.
Zutipro (hydrocodone/chlorpheniramine/pseud)	New combination antitussive/antihistamine/decongestant oral solution for relief of allergy and cold symptoms.
Zyclara (imiquimod)	New lower strength cream (3.75%) for actinic keratoses and genital warts.

Prior Authorization Updates

Drug or Class	Criteria for Coverage
Topical Ketoconazole Products	Trial of a covered ketoconazole medication
Clorpres	Trial of clonidine and chlorthalidone taken separately
Gilenya	FDA approved indication
Livalo	Trial of a covered statin
Oravig	Trial of fluconazole
Xyrem	FDA approved indication
Zyclara	Trial of imiquimod
Nuedexta	FDA approved indication
Nexiclon	Trial of clonidine
Narcotic/APAP combo products	Trial of 5/325 - 10/325

Top 25 Drugs for 2nd Quarter 2011					
Top 25 Drugs by Number of Claims			Top 25 Drugs by Total Claims Cost		
Drug	Claims Count	Paid Amount	Drug	Claims Count	Paid Amount
HYDROCOD-APAP	5,146	\$92,619.51	ABILIFY	905	\$406,161.82
AMOXICILLIN	4,269	\$104,579.46	SEROQUEL	1,130	\$354,620.49
LORAZEPAM	3,855	\$40,948.84	ZYPREXA	438	\$340,877.85
AZITHROMYCIN	3,622	\$80,949.09	SINGULAIR	1,944	\$250,426.11
OMEPRAZOLE	2,959	\$57,497.09	CONCERTA	1,566	\$249,633.61
CLONAZEPAM	2,771	\$35,128.10	ADVAIR DISKUS	800	\$175,738.86
PROVENTIL HFA	2,767	\$153,671.14	CYMBALTA	1,054	\$162,141.39
TRAMADOL HCL	2,256	\$56,018.08	VYVANSE	1,322	\$158,091.12
LEVOTHYROXINE	2,048	\$31,539.84	PROVENTIL HFA	2,767	\$153,671.14
SERTRALINE HCL	1,979	\$27,964.02	HELIXATE FS	8	\$152,182.84
SINGULAIR	1,944	\$250,426.11	LYRICA	804	\$136,689.66
FLUOXETINE HCL	1,825	\$23,089.91	DEXTRO-AMPHET	871	\$131,529.91
ALPRAZOLAM	1,761	\$18,817.69	GEODON	307	\$110,501.31
LISINOPRIL	1,722	\$32,376.83	FREESTYLE STRIPS	981	\$109,708.89
TRAZODONE HCL	1,688	\$20,482.71	BUDESONIDE	527	\$108,712.32
ZOLPIDEM	1,613	\$32,021.77	NOVOLOG	444	\$108,557.81
CONCERTA	1,566	\$249,633.61	ADDERALL XR	592	\$108,553.26
AMOX-POT-CLAV	1,566	\$66,496.64	ACTHAR H.P.	2	\$105,555.44
SULFA-TRIMETH	1,474	\$42,904.35	AMOXICILLIN	4,269	\$104,579.46
OXYCOD-APAP	1,433	\$15,117.30	LEXAPRO	1,083	\$104,305.36
ALBUTEROL SULF	1,418	\$59,245.08	STRATTERA	653	\$104,046.86
IBUPROFEN	1,400	\$51,683.92	METHYLPHEN	1,379	\$100,061.78
METFORMIN HCL	1,385	\$22,426.48	HYDROCOD-APAP	5,146	\$92,619.51
CYCLOBENZAPRINE	1,383	\$26,562.36	METADATE CD	629	\$89,412.52
METHYLPHEN	1,379	\$100,061.78	SEROQUEL XR	272	\$86,949.88
TOTAL TOP 25 BY CLAIMS COUNT	55,229	\$1,692,261.71	TOTAL TOP 25 BY CLAIMS COST	29,893	\$4,005,329.20



Health Information Designs, Inc. (HID) is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.

Health Information Designs, Inc. (HID) was founded in 1976 with a mission to improve patient care and contain costs for state Medicaid agencies by providing drug utilization review (DUR) services. In 1997, HID was acquired by HDI Solutions and subsequently has experienced strong and steady growth as a premium healthcare analytics and pharmacy support services provider. HID is the industry leader in providing comprehensive prescription drug monitoring programs. Currently, HID works with clients in 26 states, including 17 Medicaid agencies, 14 Boards of Pharmacy and state health agencies, and several private healthcare benefit management organizations. The work performed by HID has a daily impact on the healthcare of more than 67 million Americans.

HEALTH
INFORMATION DESIGNS

391 Industry Drive
Auburn, AL 36832
Tel: 800-748-0130
Fax: 800-748-0116

PRST STD
U.S. Postage